Passive Enhanced Safety Surveillance (ESS) of the Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) Fluenz Tetra in Children and Adolescents during the early 2015/2016 Influenza Season in England

Trial Profile

Passive Enhanced Safety Surveillance (ESS) of the Quadrivalent Live Attenuated Influenza Vaccine (QLAIV) Fluenz Tetra in Children and Adolescents during the early 2015/2016 Influenza Season in England

Completed
Phase of Trial: Phase IV

Latest Information Update: 28 Aug 2016

At a glance

  • Drugs MEDI 3250 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 28 Jan 2016 Accrual to date is 105% according to United Kingdom Clinical Research Network record.
    • 28 Jan 2016 Planned number of patients changed from 1000 to 156, as reported by United Kingdom Clinical Research Network record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top